Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company focused on the development of specialized cardiovascular therapies, with the late-stage asset tecarfarin, a new ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Individual patient data from neoadjuvant randomized breast cancer clinical trials with available data on pathologic complete ...

Adding the PCSK9 inhibitor led to greater absolute reductions in CVD risk than in younger patients, with no signs of safety ...

Erste Group analyst Hans Engel upgraded Amgen (AMGN) to Buy from Hold. Amgen has a higher operating margin and a higher return on equity than ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

The Dow Jones Industrial Average is climbing Wednesday afternoon with shares of Amgen and NVIDIA Corp. seeing positive growth for the index.

Alexion Pharmaceuticals v Amgen (UPC_Coa-405/2024) and Alexion Pharmaceuticals v Samsung Bioepis NL BV (UPC_CoA-402/2024); December 20, 2024.

The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

The Dow Dow Jones Industrial Average was most recently trading 148 points (0.3%) higher, as shares of Amgen Amgen Inc. and NVIDIA Corp. NVIDIA Corp. are contributing to the index's intraday rally.